Tcelltech was founded as a spin-off from DKFZ Heidelberg in 2022 and is developing personalized adoptive cell therapies. Its personalized T cell therapy has large therapeutic potential against multiple cancers and is based on two underlying technology platforms: an AI-based bioinformatics platform that allows for rapid tumor reactive T cell receptor identification and nanoSMAR a novel DNA based non-viral gene delivery system for transfecting T cells. Tcelltech is commercializing its gene delivery platform separately in non-core applications.
We are looking forward to see your active participation in the network!
You can find here more information about Tcelltech.